Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
26.02. | Impact BioMedical acquires air purifier firm Celios | 2 | Investing.com | ||
IMPACT BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
26.02. | Impact Biomedical Inc. Announces Acquisition of Celios, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality" | 1 | GlobeNewswire (USA) | ||
26.02. | DSS, Inc. Announces Sale of Celios to Impact BioMedical, Streamlining Portfolio for Strategic Growth | 193 | GlobeNewswire (Europe) | ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air... ► Artikel lesen | |
29.01. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | - | SEC Filings | ||
24.01. | IMPACT BIOMEDICAL INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
12.11.24 | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
04.11.24 | IMPACT BIOMEDICAL INC. - 8-K, Current Report | - | SEC Filings | ||
15.10.24 | Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease | 106 | GlobeNewswire (Europe) | HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker technology platform. The Canadian Intellectual... ► Artikel lesen | |
08.10.24 | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 1 | SEC Filings | ||
07.10.24 | Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates | 3 | GlobeNewswire (USA) | ||
26.09.24 | Impact BioMedical erhält neues US-Patent für Insektenschutzmittel | - | Investing.com Deutsch | ||
26.09.24 | Impact BioMedical secures new US patent for insect repellent | 1 | Investing.com | ||
26.09.24 | Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE: IBO) Announces 3F US Patent Issue | 117 | GlobeNewswire (Europe) | HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. ("IBO") is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled "Insect Repelling... ► Artikel lesen | |
20.09.24 | DSS Inc. buys $2,330 worth of Impact Biomedical shares | 1 | Investing.com | ||
19.09.24 | DSS Inc. buys Impact Biomedical shares worth over $150k | 2 | Investing.com | ||
17.09.24 | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 1 | SEC Filings | ||
17.09.24 | Impact BioMedical, Inc.: Impact BioMedical Inc. Announces the Closing of its Initial Public Offering | 211 | GlobeNewswire (Europe) | NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the... ► Artikel lesen | |
17.09.24 | Consumer wellness product developer Impact BioMedical prices IPO at $3 low end | 1 | Renaissance Capital | ||
16.09.24 | DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value | 141 | GlobeNewswire (Europe) | NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful... ► Artikel lesen | |
16.09.24 | Impact BioMedical Prices 1.5 Mln IPO At $3 Per Share | 542 | AFX News | WASHINGTON (dpa-AFX) - Impact BioMedical Inc. (IBO), Monday announced the pricing of its initial public offering of 1.5 million shares at $3.00 per share. The offering is expected to close on... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 36,200 | +1,30 % | Biotech Report: Evotec und Qiagen rutschen ab | (shareribs.com) Frankfurt / New York 07.03.2025 - Biotech-Aktien tendierten im deutschen Handel überwiegend schwächer. Evotec und Qiagen gaben nach. An der Wall Street konnte der Sektor nicht zulegen.... ► Artikel lesen | |
BIONTECH | 90,30 | -1,04 % | Konkurrenz für Novo Nordisk, BioNTech und Co: Steigen diese Biotech-Aktien bald bis zu 250%? | Für Anleger verstecken sich in der Biotech-Branche viele Papiere mit sagenhaften Kurschancen. Gerade 2 Aktien mit einem Durchhänger versprechen hohe Gewinne in der Zukunft. Die Biotech-Branche bietet... ► Artikel lesen | |
TEMPUS AI | 45,620 | 0,00 % | Cathie Wood's ARK buys Tempus AI stock, sells Block Inc | ||
EVOTEC | 6,205 | +0,16 % | Kursgewinne für die Evotec-Aktie (7,305 €) | Am deutschen Aktienmarkt liegt das Wertpapier von Evotec aktuell im Plus. Die Aktie kostete zuletzt 7,31 Euro. Ein Kursgewinn in Höhe von 19 Cent erfreut derzeit die Aktionäre von Evotec. Das Wertpapier... ► Artikel lesen | |
ADMA BIOLOGICS | 18,280 | +4,76 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
BB BIOTECH | 36,850 | +1,94 % | EQS-DD: BB BIOTECH AG: Dr. Thomas von Planta, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
06.03.2025 / 17:40... ► Artikel lesen | |
STRYKER | 335,00 | +0,21 % | Stryker Unveils Next-Generation Mako SmartRobotics but Stock Falls | ||
MINERALYS THERAPEUTICS | 13,040 | -8,04 % | Mineralys Therapeutics Aktie: Revolutionärer Fortschritt! | Die Aktie von Mineralys Therapeutics verzeichnete einen beeindruckenden Anstieg auf ein 52-Wochen-Hoch von 15,41 US-Dollar, nachdem das Unternehmen vielversprechende Ergebnisse aus seinen klinischen... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,170 | 0,00 % | Why Recursion Pharmaceuticals Stock Is Sinking Today | ||
ARVINAS | 9,020 | 0,00 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
DOGWOOD THERAPEUTICS | 10,330 | 0,00 % | Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward | ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ("Dogwood" or the "Company"), a development-stage biopharmaceutical company focused on advancing first-in-class... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,040 | +7,63 % | Evercore ISI launches Summit Therapeutics with Outperform rating | ||
SPRINGWORKS THERAPEUTICS | 50,56 | 0,00 % | SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why | ||
AMGEN | 285,45 | -2,59 % | Amgen: Novo Nordisk und Eli Lilly auf den Fersen - Dividende erhöht | Der Biotech-Gigant Amgen will es wissen und es mit dem Top-Duo im wachstumsstarken Markt für Adipositas-Medikamente, Novo Nordisk und Eli Lilly, aufnehmen. Der große Hoffnungsträger der US-Amerikaner... ► Artikel lesen | |
BEAM THERAPEUTICS | 26,870 | 0,00 % | Beam Therapeutics Reprots Positive Initial Phase 1/2 Data For BEAM-302 In AATD | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD).AATD... ► Artikel lesen |